NDAORALCAPSULE, DELAYED REL PELLETS
Approved
Jan 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
5/8 — Partial
ERYC (erythromycin) by Dr. Reddy's Laboratories is mechanism of action erythromycin acts by inhibition of protein synthesis by binding 50 s ribosomal subunits of susceptible organisms. Approved for pneumonia, acne vulgaris, blepharitis. First approved in 1981.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ERYC (Erythromycin) is an oral macrolide antibiotic approved in 1981 that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It treats gram-positive and gram-negative infections including pneumonia, acne vulgaris, and blepharitis. The drug is formulated as delayed-release capsules for oral administration.
LOE Approaching
This product is in late-stage lifecycle with no current active job listings, signaling a declining team and transitional commercial focus.
Mechanism of Action
Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Resistance The major route of resistance is modification of the 23S rRNA in the 50S ribosomal subunit to insensitivity,…
Pharmacologic Class:
Macrolide
Indications (3)
Worked on ERYC at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.